Evotec AG, through the NEU(2) consortium, has signed an agreement with Merck KGaA to develop pre-clinical candidates for an undisclosed neurological disease. Evotec will provide drug discovery expertise covering in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology. Evotec will apply its drug discovery expertise and technologies to identify small molecules for the selected target to be further optimized and progressed through lead optimization to a pre-clinical candidate. ...